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Nicotine, the active compound in cigarettes, can cause impaired glucose metabolism by 
increasing insulin resistance as well as decreasing insulin secretion in β cell pancreas. This 
condition can increase the risk of type 2 diabetes in human. This study aims to evaluate the effect 
of smoking behaviour, determined by Cigarette per Day (CPD) and smoking duration, on 
glychohemoglobine (HbA1c) levels of Javanese Indonesian smokers. 30 smokers were studied 
consisting of 7 smokers with <10 CPD, 19 smokers with 11-20 CPD and 4 smokers with 21-30 
CPD. They had been smoking for more than 10 years. The whole blood sample was used to 
examine the HbA1c levels. The HbA1c levels were tested at Bethesda Hospital's clinic 
laboratories using Architect 600 instrument. The results showed that CPD and smoking duration 
significantly influenced HbA1c, in which F count was > F table (370.541> 3.354) with 
significance < 0.05 (2.35. 10-20 < 0.05) and multiple correlation coefficient (R) of 0.982. 
Therefore, based on this research finding, it was concluded that longer smoking duration and 
higher CPD caused higher smoker’s Hba1c level. 
 




 Diabetes is one of the largest global 
health emergencies in the 21st century. The 
International Diabetes Federation has 
predicted that there will be an increasing 
prevalence of diabetics in 2033 by 2.8% over 
the past 20 years. In addition, the number of 
people affected by the disease will also 
increase by 57% from 382 to nearly 600 
million. The prevalence of diabetes has 
increased in Asian countries and it has 
contributed to more than 60% of the world’s 
diabetic population. Indonesia ranks the 
seventh highest prevalence rate of diabetes in 
the world after China, India, United States of 
America, Brazil, Mexico and Russian 
Federation (IDF, 2015). WHO estimates the 
number of patients with type 2 diabetes 
(T2DM) in Indonesia will increase 
significantly to 21.3 million in 2030. The 
estimated number of deaths due to diabetes 
among adults aged 45-54 years in urban areas 
is 14.7% while in rural areas is 5.8% (R.I., 
2009).  
T2DM has been the most prevalent form 
of diabetes and has increased alongside 
cultural and societal changes. Smoking has 
been believed to be one of the factors that can 
increase the risk of diabetes. The increasing 
risk of diabetes to smokers has been reported 
in several studies. Smokers possess 45% 
higher risk of diabetes than nonsmokers (Willi 
et al., 2007). Even though empirical data have 
shown that smoking may cause serious health 
problems in some countries, production and 
consumption of tobacco products in several 
Asian countries such as China, India and 
Indonesia still exist until now. The prevalence 
of smoking among Indonesian men was 
67.4%, which was the highest smoking rate 
Jurnal Farmasi Sains dan Komunitas, 2020, 17 (2), 76-85 
 
Association Between Smoking Behaviour… 77
7 
 
within ASEAN regions (Lian et al., 2014; 
Tandilittin et al., 2013). According to the 
Ministry of Health (2017), the percentage of 
Indonesian population with T2DM risk factor 
due to smoking activity over the age of 10 is 
24.3%.  
Several diabetes experts, namely the 
International Committee of Experts, the 
American Diabetes Association (ADA) and 
the European Association for the Study of 
Diabetes (EASD), have recommended the use 
of HbA1c to diagnose diabetes. HbA1c can be 
used to reflect average blood glucose levels 
over 3-4 months, providing a useful longer-
term measurement of blood glucose control. 
Prior to the test of HbA1c, fasting was not 
needed. Therefore, meal issues are not an 
urgent factor. Currently, HbA1c test is 
preferable because it can be done at any time, 
the value can reduce daily variation of sugar 
content and it is more reproducible. In 2011, 
ADA and WHO used HbA1c as diabetes 
diagnostic criteria with the following 
propositions; HbA1c under normal 
circumstances was 3.5% -5% and diabetes was 
confirmed if HbA1c ≥ 6.5%. If HbA1c levels 
are between 6.0 and 6.5%, it was at 
particularly high risk and might be considered 
for diabetic prevention interventions (ADA, 
2011; WHO, 2011). 
Nicotine, the active compound in 
cigarettes, is the most responsible compound 
for increasing blood sugar levels (Bajaj, 2012; 
Borowitz et al., 2008; Xie et al., 2009). 
Nicotine can cause impaired glucose 
metabolism and increase insulin resistance, 
which may lead to an increasing risk of 
developing type 2 diabetes (T2DM) (Houston 
et al., 2006; Willi et al., 2007). This study 
aims to investigate the effect of smoking 
behaviour, indicated by Cigarette per Day 
(CPD) and smoking duration, on HbA1c levels 
among Javanese Indonesian smokers. This 
research was conducted primarily in order to 




All chemicals, reagents, and solvents 
used during this study were analytical grade 
and highly pure. Ethanol 70% were purchased 
from Sigma (St. Louis, MO, USA) and we 
used sterilized water for injection from 
Ikaphamindo as a solvent. 
Instrumentations 
The HbA1c measurements were carried 
out using Arcitec 600 at Bethesda Hospital's 
clinic laboratories. 
Methods  
The study had been accomplished in 2017 
and had been approved by the Ethics 
Committees of Medical Research Duta 
Wacana University, Yogyakarta, Indonesia 
with clearance number of 424/C.16/FK/2017. 
A total of 30 male healthy Javanese 
Indonesian smokers were recruited from 
Sanata Dharma University staffs who had been 
involved in previous studies of CYP2A6 *1, 
CYP2A6 *4, and CYP2A6 *9 genotypes. 
Research subjects had smoked for minimum 
10 years, were not currently planning to stop 
smoking, were between 20 and 45 years-old, 
had body weight between 46 and 75 kg with 
height varying between 150 and 170 cm, took 
no concurrent medications, and had no 
illnesses requiring investigation or treatment. 
Smoking status was collected based on 
questionnaires which requested information on 
the number of cigarettes smoked per day 
(CPD), the age at which the subject started 
smoking, and other tobacco products used. All 
of smoking subjects were cigarette smokers. 
Smokers with a family history of diabetes 
were excluded from this study. 
Venous blood samples from all the 
subjects were collected in vacutainer tubes. 
The tubes were labelled and used to determine 
the HbA1c levels. The subjects had been given 
informed consent prior to participating in this 
study. The HbA1c examination was performed 
at Bethesda Hospital's clinic laboratories using 
Architect 600 instrument. 
The data were analyzed using Microsoft 
Excel 2016. We conducted t-test and ANOVA 
test to examine the effect of smoking 
behaviour, determined by CPD and smoking 
duration, on HbA1c levels. The multi-liner 
regression analysis was used to examine 
correlation between CPD and smoking 
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duration with HbA1c. P values <0.05 were 
considered as statistically significant. 
 
RESULTS AND DISCUSSION 
 Diabetes mellitus is one of serious 
problems on public health where many people 
are unaware to suffer from this disease. 
Diabetes in Indonesia, mostly T2DM caused 
by lifestyle, was growing precipitously. 
Smoking, another public health problem 
encountered by Indonesia, is one of lifestyle 
factors causing diabetes. The subjects involved 
in this study were active smokers who had 
smoked cigarettes for a minimum of 10 years 
with CPD between 8-30 cigarettes per day. 
According to Fagerstrom Test for Nicotine 
Dependence (FTND), the number of smoker’s 
CPD is categorized into four criteria; 10 or 
less, 11-20, 21-30 and 31 or more cigarettes. 
Based on these criteria, the subjects The 
subjects involved in this study were active 
smokers who had smoked cigarettes for a 
minimum of 10 years with CPD between 8-30 
cigarettes per day. According to Fagerstrom 
Test for Nicotine Dependence (FTND), the 
number of smoker’s CPD is categorized into 
four criteria; 10 or less, 11-20, 21-30 and 31 or 
more cigarettes. Based on these criteria, the 
subjects involved in this research were 30 
smokers consisting of 7 smokers with CPD 
<10 cigarettes, 19 smokers with CPD between 
11-20 cigarettes and 4 smokers with CPD 
between 21-30 cigarettes.  
In another CYP2A6 genotype study, it 
was found not only active form CYP2A6*1 
but also a non-active allele, CYP2A6*4 and 
CYP2A6*9 alleles in the population. The 
alleles frequencies among the subjects were 
48.5% (CYP2A6*1), 48.5% (CYP2A6*4) and 
3% for CYP2A6*9 respectively (Patramurti 
and Fenty, 2019). All subjects were 
categorized as slow metabolizers with 28 
subjects had a CYP2A6*1/*4 genotype and 
two subjects had CYP2A6*1/*4/*9 genotype. 
CYP2A6 is an enzyme responsible for nicotine 
metabolism, and it transforms nicotine into 
inactive form, i.e., cotinine and 3-




Figure 1. The main metabolism of nicotine mediated by CYP2A6 
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Table 1. Characteristics and distribution of HbA1 content test subjects 
Distribution 
Characteristics 
CPD Smoking Duration (year) HbA1c (%) 
Mean ± SD 14 ± 1 23,57 ± 1,22 5,28 ± 0,082 
Range 6 - 30 14 - 36 4,83 - 7,16 
Median 12 23,5 5,28 
    
The polymorphic form of CYP2A6 in the 
subjects will lead to a decreasing CYP2A6 
activity in metabolizing nicotine. Slow 
metabolizers of nicotine will decrease nicotine 
metabolism. Furthermore, increasing exposure 
to nicotine often leads to increasing nicotine 
levels in the blood and creates increasing 
blood sugar levels. According to Liu et al. 
(2011), smokers categorized as slow 
metabolizers or poor metabolizers (having 
alleles * 4 and * 9) are more susceptible to 
T2DM than smokers categorized as normal 
metabolizers or intermediate metabolizers.  
The risk of T2DM in this study was 
expressed by HbA1c parameters. According to 
ADA (2014) HbA1c levels are classified into 
3 groups, i.e. normal (<5.7%), prediabetes (5.7 
- 6.4%) and diabetes (≥ 6.5). The smokers’ 
HbA1c levels will be higher than those 
nonsmokers (Jyothirmayi et al., 2013; Nilsson, 
et al., 2004; Padhy et al., 2015; Vlassopoulos, 
Lean et al., 2013). The characteristics of the 
subjects covering CPD, duration of smoking, 
and distribution of HbA1c levels are shown in 
table 1.  
From table 1, it can be seen that the 
average CPD is 14 cigarettes per day. All 
subjects had been smoking for more than 10 
years, meaning that each subject had been 
exposed to nicotine for a long time. The 
average HbA1c levels in all the 30 subjects 
were still in normal conditions with mean 
scores 5.28 ± 0.082 %, respectively. The range 
of HbA1c levels was 4.83-7.16. It showed that 
there were some subjects with diabetic 
condition. In the measurement of HbA1c 
levels, it was revealed that HbA1c levels of 25 
test subjects were still normalized within range 
of 4.83-5.56%; 4 subjects were identified in 
prediabetic condition within range of 5.7-
5.97% and 1 subject had diabetes with HbA1c 
level of 7.16%. These conditions indicate that 
smoking behaviour affects HbA1c levels 
which can lead to the occurrence of T2DM 
disease. This finding is in line with several 
studies which reveal the association between 
active smoking and T2DM incidence 
worldwide (Hang, 2011; Jee et al., 2010; 
Kowall et al., 2010; Peter et al., 2014; Saeed, 
2012).  In addition, several other studies have 
also shown that exposure to environmental 
tobacco smoke (ETS) which contain nicotine 
towards passive smokers can also increase the 
risk of T2DM (Wang et al., 2013; Yeh et al., 
2010). 
Smoking behaviour in this study was 
observed from two elements namely CPD and 
duration of smoking. The effect of CPD and 
duration of smoking on HbA1c levels was 
partially analyzed using t test. In t test 
conducted on each variable, the t value of 
CPD was > t table (3.689> -2.0480) with 
significance <0.05 (0.001 <0.05). Likewise, 
the t value of duration of smoking was > t 
table (8.586> -2.048) with significance <0.05 
(0.000 <0.05). Based the t test on each 
variable, it can be concluded that both CPD 
and duration of smoking can partially 
influence HbA1c levels. Due to these findings, 
the analysis was continued using ANOVA test 
which would observe the effect of CPD and 
duration of smoking on HbA1c levels 
simultaneously. Anova test shows that F value 
was > F table (370.541> 3.354) with 
significance <0.05 (2.35.10-20 <0.05). This 
suggests that CPD and long smoking have a 
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simultaneously significant effect on HbA1c 
levels. 
The relationship between smoking 
behaviour, e.g. CPD and smoking duration, 
and HbA1c levels in this research was 
analyzed by multiple correlations using 
correlation coefficient parameter R. There was 
a significant correlation between CPD and 
smoking duration with HbA1c (R=0.982, P < 
0.001). This result indicated that there was a 
statistically close relationship of CPD and 
smoking duration with HbA1c levels. The R 
value in this study was positive which means 
that CPD, smoking duration, and smokers’ 
HbA1c levels have positive correlation. These 
results suggest that the risk of T2DM indicated 
by HbA1c will increase with interaction of 
cigarettes smoked and smoking duration. 
Higher risk of T2DM had been observed in 
smokers who started smoking at age 18 years 
old or younger. Starting smoking at a younger 
age might be associated with greater 
dependence and heavy smoking patterns 
(Kawakami et al., 1997). These results also 
support many other previous studies which 
state that the more cigarettes a smoker smokes, 
the higher the T2DM risk is (Foy et al., 2005; 
Liu et al., 2011; Nakanishi et al, 2000; Will et 
al., 2001). The R square for the regression 
analysis was 0.963. This means that the 
percentage contribution of CPD and smoking 
duration to HbA1c levels was 96.3% while the 
rest 3.7% was related to other variables which 
were not included in this study. 
The relationship between smoking 
behaviour, which is indicated by CPD and 
smoking duration, and HbA1c levels was 
formulated by the following equation: Y = 
0.106 X2 + 0.152 X1, where: Y is HbA1c, X1 
is CPD, and X2 is the duration of smoking. 
Based on this equation, it can be seen that the 
magnitude of the influence of CPD and 
smoking duration on HbA1c levels is for as 
much as 0.106 and 0.152 respectively. Thus, if 
it is assumed that the duration of smoking is 
constant, each cigarrete smoked will cause an 
increase on HbA1c levels for as much as 
0.106%. On the other hand, if CPD does not 
change, each year of smoking duration will 
contribute to the increase of HbA1c level for 
as much as 0.152%. The relationship curve 
between CPD and duration of smoking with 
HbA1c levels is illustrated in the following 
figure 2. Based on those equations, pre-
diabetic condition of a smoker will occur at 
least if the number of cigarettes smoked per 
day is as many as 20 cigarettes with a 
minimum smoking duration of 25 years. 
Meanwhile, diabetic condition of a smoker 
will occur at least if the number of cigarettes 
smoked per day is as many as 20 cigarettes 
with a minimum smoking duration of 29 years. 
Based on these results, chronic cigarette 
smokers will have a high risk of T2DM. 
Therefore, it is possible for smokers who 
smoke less than 20 cigarettes per day to be 
exposed to T2DM if they never stop their 
smoking habit.  
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Figure 2. Relationship curve between CPD and duration of smoking with HbA1c levels. The colors show predicted 
        HbA1c value caused by interaction of smoking duration and CPD. 
 
Nicotine, the active compound in 
cigarette, could decrease insulin sensitivity. In 
human skeletal muscle and muscle cell 
cultures, nicotine could interact with nicotinic 
acetylcholine α1 receptors. Due to this 
interaction,  mammalian target of rapamycin 
(mTOR/p70S6) and insulin receptor substrate-
1(IRS-1) Ser636 phosphorylation will be 
activated and it causes insulin resistance or 
impairment of pancreatic β cells which lead to 
induced insulin resistance inhibit and inhibit 
insulin secretion insulin (Bajaj, 2012; 
Bergman et al., 2012). Once insulin resistance 
occurs, the absorption of glucose in the tissue 
will be disrupted and the blood glucose levels 
will increase. Other than this, nicotine can also 
inhibit the secretion of insulin. The effect of 
nicotine on insulin secretion is caused by an 
interaction of nicotine to nicotinic 
acetylcholine receptors on β-cells and it will 
increase apoptosis of islet β-cells (Xie et al., 
2009). Due to this condition, the occurrence of 
long-lasting exposure to nicotine in a smoker 
will increase the risk of T2DM disease.  
 Some meta-analysis studies have shown 
that nicotine exposure over long periods will 
lead to increased metabolic syndrome (Chang, 
2012; Harris et al., 2016; Sun et al., 2012). 
Smoking is known to reduce body weight; it is 
linked with central obesity. Stadler et al. 
(2014) find that higher triglycerides and lower 
High Density Lipoprotein (HDL) cholesterol 
which play role as major determinants in the 
development of T2DM in predisposed 
individuals can be triggered by chronic 
smoking. Nicotine can rise the concentration 
of free fatty acids in a smoker’s blood by 
triggering an increasement in the breakdown 
of fats (lipolysis). This chronic rise in the 
concentration of fatty acids unfavorably 
affects insulin sensitivity and insulin secretion 
through direct effects on liver, pancreas and 
muscle. It has also been recommended that the 
distribution of a smoker’s body fat has been 
directly influenced by chronic tobacco 
smoking (Targher, 2005; Loria et al., 2013). 
Further studies are needed to explore the role 
of association between triglycerides and HDL 
levels with HbA1c among Javanese 
Indonesian smokers.  
 Based on these results, we concluded that 
an important aspect to avoid T2DM is a 
prevention of smoking in early life. According 
to Bergman et al. (2012), insulin resistance 
and sensitivity caused by nicotine are 
reversible with smoking cessation. Therefore, 
to prevent the occurrence of diabetes, a 
smoker must stop smoking activities. Some 
other studies suggest that it is important to 
motivate smokers particularly with diabetes to 
stop smoking than general smoker population 
(Reinhard et al., 2006; Cho et al., 2009; 
 0.00-2.00  2.00-4.00  4.00-6.00  6.00-8.00 
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Nilsson et al., 2014; Luo et al., 2013). The 
form of CYP2A6 allele owned by a person 
will affect whether it is easy for a smoker to 
quit smoking. Several studies conducted on 
adult smokers show that smokers with inactive 
allele types (CYP2A6*4 or *9) have less 
number of CPD and lower tendency to 
cigarette dependence compared to smokers 
who have active allele type (CYP2A6 * 1) 
(Chenoweth et al., 2013; O’Loughlin, 2004; 
Schoedel et al., 2004).  In addition, smokers 
with inactive alleles have a tendency to quit 
smoking more easily (Ando et al., 2003; 
Ariyoshi et al., 2002; Fujieda et al., 2004; 
Minematsu et al., 2006; Rao et al., 2000). 
According to Padmawati et al. (2009), as 
much as 65% of subjects tested T2DM in 
Yogyakarta had a history of smoking before 
they were diagnosed with T2DM, even some 
patients with T2DM still smoked regardless of 
the risks. This was due to the absence of 
integrated effort from related parties to seek 
program to stop smoking. In Indonesia, where 
there are a high consumption rate of cigarette 
and a rapidly increasing prevalence of 
diabetes, we conclude that reducing the burden 
of T2DM can be done by cigarette cessation 
strategies which might pose some advantages. 
The burden illness caused by smoking will be 
reduced if health professionals encourage 
smoking cessation. Future study is required to 
further explain the relation between smoking 
cessation and prevalence of T2DM. 
 There are several important limitations in 
this study. The confounding factors like 
obesity, physical activity, and dietary factors 
have not been investigated. Further study is 
needed to investigate clinical significance of 
the result of this research. These results 
support other studies stating that smoking 
leads to increasing blood glucose levels and 
HbA1c levels which may lead to T2DM if 
smoking is not controlled. 
 
CONCLUSION 
In conclusion, our study suggests that 
interaction between the number of cigarettes 
smoked and smoking duration is strongly and 
independently associated with the risk of 
T2DM in smokers indicated by HbA1c. 
Chronic smokers, either light or intermediate 
smokers, who have been classified as slow and 
poor metabolizer genotypes will have high risk 
to suffer from T2DM. There are several 
limitations in this study in which several 
possible contributing variables have not yet 
been included. Those variables might be 
confounding to our results, for example 
obesity, physical activity, dietary factors and 
biochemical variation such as plasma nicotine 
levels or total urinary nicotine equivalents. 
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